Reversing resistance: The next generation antibacterials

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Rising antimicrobial resistance (AMR) poses a significant threat, risking a return to the pre-antibiotic era.
• Nosocomial infections caused by multidrug-resistant organisms like Enterococcus, Staphylococcus, and Pseudomonas are increasingly difficult to treat.
• The emergence of enzymes such as extended-spectrum β-lactamases, carbapenemases, and metallo-β-lactamases exacerbates treatment challenges.

Purpose of the Study:

• To highlight the critical threat of multidrug resistance (MDR) driven by irrational antibiotic usage.
• To discuss current strategies and initiatives aimed at combating AMR, including the development of new antibiotics.
• To identify novel targets within bacterial machinery for future therapeutic interventions.

Main Methods:

• Review of existing antibiotic classes effective against resistant bacteria (e.g., carbapenems, oxazolidinones).
• Discussion of ongoing synthesis of newer drugs within established antibiotic classes.
• Identification of potential new antibacterial targets, including peptidoglycan transferase and mycobacterial ATP synthase.

Main Results:

• The global spread of multidrug resistance is an imminent crisis with limited therapeutic options.
• Initiatives like the Infectious Disease Society of America's 10x'20 plan aim to develop new antibiotics.
• Research is exploring novel targets in bacterial cellular machinery to overcome resistance mechanisms.

Conclusions:

• Urgent development of novel antibiotics and innovative therapeutic targets is essential.
• Stricter regulation and control of current antibiotic usage are paramount to preserve their efficacy.
• A multi-pronged approach involving new drug discovery and responsible antibiotic stewardship is required to combat AMR.